	Application No.	Applicant(s)
Notice of Allowability	10/627,978	RITZELER ET AL.
	Examiner	Art Unit
	Zinna Northington Davis	1625
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. X This communication is responsive to the Amendment filed July 18, 2005.		
2. X The allowed claim(s) is/are 35-37 and 42-52 (now renumbered as 1-14, respectively).		
3. ☑ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) ☐ All b) ☐ Some* c) ☐ None of the:		
1. Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No. <u>09/812,785</u> .		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached		
1)  hereto or 2)  to Paper No./Mail Date		
(b) 🔲 including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)		
1. Notice of References Cited (PTO-892)	5. Notice of Informal P	atent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. X Interview Summary	
<ul> <li>3.</li></ul>	Paper No./Mail Date 7. ⊠ Examiner's Amendment/Comment	
	8. 🛛 Examiner's Stateme	ent of Reasons for Allowance
	9.	9.
		,

Page 2

Application/Control Number: 10/627,978

Art Unit: 1625

## **EXAMINER'S AMENDMENT**

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Steven Scott on September 27, 2005.

- 2. The application has been amended as follows:
  - A. Claim 52 has been amended to read as follows:
- --52. (Previously Presented) A method for treating a patient experiencing at least one disorder involving an increased activity of I<sub>K</sub>B kinase where the disorder is atherosclerosis, the method comprising administering to the patient an efficacious amount of at least one compound chosen from a compound of formula I as set forth in claim 35, a stereoisomeric form of a compound of the formula I, or a physiologically tolerable salt of a compound of the formula I--.
  - B. Claims 53-65 have been cancelled.

## **REASONS FOR ALLOWANCE**

The following is an examiner's statement of reasons for allowance:

- 3. The previously withdrawn method claim has been rejoined.
- 4. Applicants preserve the right to file divisional applications drawn to the non-elected subject matter.

Application/Control Number: 10/627,978 Page 3

Art Unit: 1625

The Examiner's Amendment limits the method claim to a disorder, which is 5. atherosclerosis. Based upon this change, the claims meet the requirements, under 35

USC §112, 1<sup>st</sup> paragraph. In the specification, support is found at page 70, lines 5-14.

This amendment is not made to avoid any possible rejections based upon prior art.

7. Any comments considered necessary by applicant must be submitted no later than

the payment of the issue fee and, to avoid processing delays, should preferably

accompany the issue fee. Such submissions should be clearly labeled "Comments on

Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Zinna N. Davis whose telephone number is 571-272-

0682.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published

applications may be obtained from either Private PAIR or Public PAIR. Status

information for unpublished applications is available through Private PAIR only. For

more information about the PAIR system, see http://pair-direct.uspto.gov. Should you

have questions on access to the Private PAIR system, contact the Electronic Business

Center (EBC) at 866-217-9197 (toll-free).

**Primary Examiner** 

Group 1600-AU 1625